November 21, 2016 - By Louis Casey · 0 Comments
Heat Biologics Inc (NASDAQ:HTBX) institutional sentiment increased to 2.67 in Q2 2016. Its up 2.37, from 0.3 in 2016Q1. The ratio has increased, as 3 hedge funds opened new or increased stock positions, while 10 decreased and sold their stock positions in Heat Biologics Inc. The hedge funds in our partner’s database now own: 1.66 million shares, down from 2.72 million shares in 2016Q1. Also, the number of hedge funds holding Heat Biologics Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 4 Increased: 2 New Position: 1.
Heat Biologics, Inc. is a development-stage firm focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The company has a market cap of $36.18 million. The Firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). It currently has negative earnings. Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC).
About 1.46M shares traded hands or 108.98% up from the average. Heat Biologics Inc (NASDAQ:HTBX) has risen 111.94% since April 19, 2016 and is uptrending. It has outperformed by 108.08% the S&P500.
According to Zacks Investment Research, “Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina.”
Franklin Street Advisors Inc Nc holds 0.01% of its portfolio in Heat Biologics Inc for 70,500 shares. Bank Of America Corp De owns 5,000 shares or 0% of their US portfolio. Moreover, Blackrock Advisors Llc has 0% invested in the company for 2,991 shares. The California-based Blackrock Fund Advisors has invested 0% in the stock. Franklin Resources Inc, a California-based fund reported 1.33 million shares.#img1#
Ratings analysis reveals 100% of Heat Biologics’s analysts are positive. Out of 4 Wall Street analysts rating Heat Biologics, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.75 while the high is $18. The stock’s average target of $12.44 is 723.84% above today’s ($1.51) share price. HTBX was included in 5 notes of analysts from September 1, 2015. Cantor Fitzgerald maintained it with “Buy” rating and $18 target price in Tuesday, September 1 report. The firm has “Buy” rating by Roth Capital given on Monday, June 20. H.C. Wainwright maintained the shares of HTBX in a report on Thursday, September 3 with “Buy” rating. The rating was initiated by Noble Financial on Friday, January 8 with “Buy”. The firm has “Speculative Buy” rating given on Thursday, February 4 by Cantor Fitzgerald.
Heat Biologics, Inc., incorporated on June 10, 2008, is a development-stage firm focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Firm is an immuno-oncology firm developing therapies intended to activate a patient’s immune system to fight cancer. The Company, by using its T cell-stimulating platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), has generated several product candidates for treating certain forms of cancer. The Company’s platform technologies address over two synergistic mechanisms of action, including the activation of CD8+ T cells, or killer T cells, and T cell co-stimulation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey